Vimarsana
Biggest News Aggregation in the World

Page 9 - David Cory News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from David Cory. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In David Cory Today - Breaking & Trending Today

Bridging the worlds of research and industry - Vimarsana News

Bridging the worlds of research and industry

Nidhi Juthani is a student in MIT’s PhD in Chemical Engineering Practice (PhDCEP) program, which allows her to obtain a doctorate and an MBA concurrently. The combination is a perfect fit for Juthani, who wants to pursue a career straddling scientific research and industry.

Source: mit.edu
Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones - Vimarsana News

Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection - Vimarsana News

Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection - Vimarsana News

Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

Eiger receives DSMB advice to continue Phase III Covid-19 therapy trial - Vimarsana News

Eiger receives DSMB advice to continue Phase III Covid-19 therapy trial

Eiger has received a recommendation from the DSMB to continue the Phase III TOGETHER clinical trial of Peginterferon Lambda without changes.